Psoriasis Vulgaris
Conditions
Brief summary
The purpose of this observational study is to evaluate the efficacy, tolerability, quality of life and handling of Daivobet® Gel by both physician and patient in daily practise.
Interventions
DRUGDaivobet® Gel
Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
Sponsors
LEO Pharma GmbH, Neu-Isenburg, Germany
LEO Pharma
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with light to moderate psoriasis vulgaris of trunk and extremities and treatment with Daivobet® Gel was planned anyway
Exclusion criteria
* Previous therapy with Daivobet® Gel * Systemic therapy of psoriasis vulgaris * Contraindications of Daivobet® Gel in the German package insert
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Handling of Daivobet® Gel | After appr 4 weeks | Compared to previous topical treatment: Time required for application (previous treatment versus present treatment), time required until dressing is possible (previous treatment versus present treatment) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life | 4 weeks | Dermatology Life Quality Index (DLQI) |
| Physician's global Assessment of psoriasis vulgaris | 4 weeks | 6-step scale from no visible disease (O) to very severe disease (5) |
| Side effects | 4 weeks | number of participants with serious and non-serious adverse drug reactions, according to organ classes |
Countries
Germany
Outcome results
None listed